Singular Genomics

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

Singular Genomics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $6.3B in funding across 36 round(s). With a team of 51-100 employees, Singular Genomics is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - Singular Genomics, raised $130.5M. Discover more about their projects, partnerships, and impact on our platform.